A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Low-Dose Human Interferon-Alpha by the Oral Mucosal Route During the 6-Month Follow-up Period of Standard Combination Therapy for Hepatitis C Virus Infection.
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2017
At a glance
- Drugs Interferon alpha (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 06 Sep 2017 Results published in an Amarillo Biosciences media release.
- 10 Jun 2017 Biomarkers information updated
- 14 Jun 2012 Primary endpoint 'Virological-relapse-rate' has not been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History